Jefferies Says Buy Neurocrine Bio. (NBIX) Ahead of Catalyst

February 11, 2013 10:18 AM

Jefferies raised its price target on Buy-rated Neurocrine Bio. (NASDAQ: NBIX) from $13 to $14 following Q4 results and 2013 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found